...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!
Message: Here is the cached version.....
And here's a cut and paste of what slide #5 says.....RVX should be halted before a single trade takes place and the company needs to disclose what is going on before it restarts:
| Page 1 |
Resverlogix Corp. (TSX:RVX)
BIO International Convention
San Diego, CA.
June 2017
R E S V E R L O G I X . c o m
T S X : R V X
This presentation may contain certain forward-looking information as defined under
applicable Canadian securities legislation, that are not based on historical fact,
including without limitation statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate",
"forecasts" and other similar expressions. In particular, this news release includes
forward looking information relating to the potential role of apabetalone in the
treatment of cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney
disease (CKD), end-stage renal disease treated with hemodialysis, Alzheimer's
disease, Alkaline phosphatase (ALP), Fabry’s disease, and Orphan diseases. Our
actual results, events or developments could be materially different from those
expressed or implied by these forward-looking statements. We can give no
assurance that any of the events or expectations will occur or be realized. By their
nature, forward-looking statements are subject to numerous assumptions and risk
factors including those discussed in our Annual Information Form and most recent
MD&A which are incorporated herein by reference and are available through
SEDAR at www.sedar.com. The forward-looking statements contained in this news
release are expressly qualified by this cautionary statement and are made as of the
date hereof. The Company disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
Forward Looking Statements
2
Corporate Overview
R E S V E R L O G I X . c o m
T S X : R V X
• Resverlogix Corp. (TSX:RVX) is a Calgary and San Francisco
based clinical stage biotechnology company focused on the
development of apabetalone
• Apabetalone (RVX-208) is a first-in-class small molecule selective
BET bromodomain inhibitor, which acts via an epigenetic
mechanism that can turn disease-causing genes off, thereby
normalizing gene function
– Apabetalone is the only selective BET bromodomain inhibitor in clinical trials
• Resverlogix has initiated clinical trials of apabetalone in three
indications:
– Cardiovascular Disease (BETonMACE Trial)
– Chronic Kidney Disease (BETonRENAL Trial)
– Fabry’s Disease
Corporate Overview
4
R E S V E R L O G I X . c o m
T S X : R V X
Capitalization and Financial Profile
Founded
2001
Ticker
TSE-RVX
Market Cap
~C$155.3M
Debt
~C$117.6M
Shares
Outstanding
112.2M
~132M fully diluted
Loading...
Loading...
New Message
Please
login
to post a reply